Skip to ContentGo to accessibility pageKeyboard shortcuts menu
OpenStax Logo

Case Study

1.
c. Enalapril is an ACE inhibitor that can cause hyperkalemia (a high potassium level).
2.
b. Furosemide is a loop diuretic and is used to decrease fluid volume.

Review Questions

1.
d. Cardiac output is composed of heart rate × stroke volume. Normal resting cardiac output is 4–5 liters per minute.
2.
d. Lisinopril inhibits the enzyme that converts angiotensin I to angiotensin II.
3.
c. 7.5 m g ÷ 2.5 m g = 3 t a b l e t s .
4.
c. Sacubitril inhibits neprilysin, which is an enzyme that breaks down BNP. BNP stimulates vasodilation and sodium and water excretion, which decrease afterload and preload, respectively.
5.
a. Valsartan and spironolactone can cause potassium to be reabsorbed in the nephron. Clients are at risk for hyperkalemia.
6.
c. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor and has received FDA approval for use in the treatment of heart failure.
7.
c. 60 m g ÷ 40 m g = 1.5 o r 1 1 2 t a b l e t s .
8.
c. Research has shown that beta blockers and medications affecting the RAAS do not work as well in the treatment of heart failure for Black clients as hydralazine and isosorbide dinitrate do.
9.
d. Digoxin is a cardiac glycoside and slows the heart rate. It can cause bradycardia. The health care provider should be notified before administering this drug.
10.
b. Ivabradine is an I(f) current inhibitor. Grapefruit juice increases blood levels of ivabradine by inhibiting its metabolism. The excess amount of medication can intensify the medication’s hypotensive effect, placing the client at an increased risk for syncopal episodes.
Citation/Attribution

This book may not be used in the training of large language models or otherwise be ingested into large language models or generative AI offerings without OpenStax's permission.

Want to cite, share, or modify this book? This book uses the Creative Commons Attribution License and you must attribute OpenStax.

Attribution information
  • If you are redistributing all or part of this book in a print format, then you must include on every physical page the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
  • If you are redistributing all or part of this book in a digital format, then you must include on every digital page view the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
Citation information

© May 15, 2024 OpenStax. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution License . The OpenStax name, OpenStax logo, OpenStax book covers, OpenStax CNX name, and OpenStax CNX logo are not subject to the Creative Commons license and may not be reproduced without the prior and express written consent of Rice University.